Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC grew its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 8.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,558 shares of the medical equipment provider’s stock after acquiring an additional 662 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Zimmer Biomet were worth $960,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Brown Brothers Harriman & Co. increased its holdings in Zimmer Biomet by 4.0% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 2,063 shares of the medical equipment provider’s stock worth $300,000 after buying an additional 80 shares during the period. Glenview Trust Co lifted its position in shares of Zimmer Biomet by 1.5% during the 2nd quarter. Glenview Trust Co now owns 5,564 shares of the medical equipment provider’s stock valued at $810,000 after buying an additional 84 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Zimmer Biomet by 5.7% during the 2nd quarter. Parallel Advisors LLC now owns 1,583 shares of the medical equipment provider’s stock valued at $231,000 after buying an additional 85 shares in the last quarter. Bradley Foster & Sargent Inc. CT lifted its position in shares of Zimmer Biomet by 1.3% during the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 6,452 shares of the medical equipment provider’s stock valued at $823,000 after buying an additional 85 shares in the last quarter. Finally, Private Advisor Group LLC lifted its position in shares of Zimmer Biomet by 1.0% during the 2nd quarter. Private Advisor Group LLC now owns 9,475 shares of the medical equipment provider’s stock valued at $1,357,000 after buying an additional 91 shares in the last quarter. Institutional investors and hedge funds own 87.48% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on ZBH shares. Truist Financial raised their price objective on Zimmer Biomet from $133.00 to $135.00 and gave the company a “hold” rating in a report on Friday, February 9th. JPMorgan Chase & Co. increased their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Royal Bank of Canada restated an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 9th. JMP Securities decreased their price objective on Zimmer Biomet from $160.00 to $140.00 and set a “market outperform” rating on the stock in a research note on Monday, November 13th. Finally, Raymond James lifted their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $138.20.

Read Our Latest Research Report on ZBH

Zimmer Biomet Stock Up 1.2 %

ZBH opened at $125.45 on Tuesday. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $149.25. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The stock’s fifty day moving average is $123.65 and its 200-day moving average is $117.10. The company has a market capitalization of $25.73 billion, a PE ratio of 25.65, a P/E/G ratio of 2.12 and a beta of 1.01.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the previous year, the business earned $1.88 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.77%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is 19.63%.

Insider Activity

In related news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by company insiders.

About Zimmer Biomet

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Featured Articles

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.